目前胃癌是我国发病率和死亡率分别居于第5位和第3位的恶性肿瘤,给居民生命健康和我国卫生经济带来巨大负担.由于胃癌的早期筛查仍未全面普及,我国近一半的胃癌患者发现时已是晚期,预后不良.近年来,随着抗肿瘤新药临床研究的不断推进,新型药物的研发和上市给晚期胃癌患者带来了新的治疗机会.本文汇总近10年晚期胃癌领域新药临床研究,从靶向治疗、免疫治疗、抗血管生成治疗和新型化疗药物等不同角度,分析和阐述晚期胃癌内科治疗中的临床研究进展,并对未来研究进行展望,以在此基础上期待开展更加高质量的临床研究,更进一步改善晚期胃癌患者的生存和预后.
Gastric cancer occupies the fifth and third place in the incidence and mortality rates in our country,respectively,which brings great burden to the patients'life.As the early screening of gastric cancer has not been fully popularized,nearly half of patients with gastric cancer in China have been found to be of advanced stages and have a poor prognosis.In recent years,with the continuous breakthroughs of clinical trials on new anti-tumor drugs,the approvement of new drugs have brought new opportunities for advanced gastric cancer patients.This review summarizes clinical trials in the field of advanced gastric cancer in the past decade,analyzes and expounds the progress of clinical trials in the internal medical treatment of advanced gastric cancer from different perspectives such as targeted therapy,immuno-therapy,anti-angiogenic therapy and new chemotherapy drugs,and forecasts future directions.On this basis,more high-quality clinical trials are expected to be carried out,in order to improve the survival and prognosis of patients with advanced gastric cancer.
薛俊丽
同济大学附属东方医院肿瘤科,上海 200123
晚期胃癌;抗肿瘤新药;临床研究
advanced gastric cancer;new anti-tumor drugs;clinical trials
《实用肿瘤杂志》 2024 (003)
193-201 / 9
国家自然科学基金(82260562,82372922);上海市浦东新区优秀学科带头人计划(PWRd2021-09)
10.13267/j.cnki.syzlzz.2024.031
评论